← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Almenoff June Sherie
Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001492647
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 2
- Purchases · 24M
- 3
- Average purchase
- $14.2K
- Median purchase
- $15.0K
- Gross purchase value
- $42.7K
Companies: Avalo Therapeutics, Inc. | TENAX THERAPEUTICS, INC.
3 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2025-11-20 | TENAX THERAPEUTICS, INC. | TENX | Director | $15.0K | Open filing |
| 2025-11-19 | TENAX THERAPEUTICS, INC. | TENX | Director | $15.0K | Open filing |
| 2024-11-14 | Avalo Therapeutics, Inc. | AVTX | Director | $12.8K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small Sample | 66.7% (2/3) | 100.0% (2/2) | +22.2% | +22.2% | +17.7% |
| 20D | 2Small Sample | 66.7% (2/3) | 100.0% (2/2) | +69.2% | +69.2% | +65.4% |
| 60D | 2Small Sample | 66.7% (2/3) | 100.0% (2/2) | +61.5% | +61.5% | +56.1% |
| 120D | 2Small Sample | 66.7% (2/3) | 100.0% (2/2) | +45.3% | +45.3% | +41.6% |
Research patterns
- First purchase in 12M
- 1/2
- Large purchase ≥ $100k
- 0/3
- Cluster buying · 15D
- 2/3
- Buying the dip
- 0/2
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.